Stay updated with breaking news from Alimera Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com assumed coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a report published on Friday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reaffirmed a buy rating and set a $5.00 price target on shares of Alimera Sciences in a report on Monday, August 14th. […]
ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be...
– Positive masked safety data update for EYP-1901 in ongoing PAVIA and DAVIO 2 Phase 2 clinical trials as of October 1, 2023 with no drug related ...
31.10.2023 - ATLANTA, Oct. 31, 2023 (GLOBE NEWSWIRE) - Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining ...
StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM – Free Report) in a research report sent to investors on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reiterated a buy rating and set a $5.00 target price on shares of Alimera Sciences in a research report on […]